Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Astex, Daiichi Sankyo, Inc, Foundation Medicine, Inc., Genentech, and Jazz Pharmaceuticals, Inc.

Community Practice Connections®: New Therapies for Better Patient Outcomes in Acute Myeloid Leukemia: Integration of Recent Data Sets Into Clinical Practice

Release Date: February 28, 2019
Expiration Date: February 28, 2020
Media: Internet - based

Activity Overview

Community Practice Connections: New Therapies for Better Patient Outcomes in Acute Myeloid Leukemia: Integration of Recent Data Sets Into Clinical Practice consists of a series of interactive clinical vignettes, short video interviews of leading experts in acute myeloid leukemia (AML), and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Astex, Daiichi Sankyo, Inc, Foundation Medicine, Inc., Genentech, and Jazz Pharmaceuticals, Inc.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists/hematologists, nurse practitioners, nurses, and fellows who treat and manage patients with AML. Physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of AML are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  1. Identify prognostic factors for risk stratification in patients with AML, methods to apply testing strategies and their findings, and monitoring strategies for patients managed for these tumors
  2. Detail results from recent clinical trials that have evaluated emerging treatment strategies for patients with AML
  3. Apply emerging data sets in the context of evolving treatment paradigms in the management of AML
  4. Apply evidence-based strategies for proactive management of treatment-related toxicities that occur in the real-world management of patients with AML

Faculty, Staff, and Planners' Disclosures


Naval G. Daver
Naval G. Daver, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: BMS, Pfizer, Incyte, AbbVie, Daiichi Sankyo, Inc, Genentech, Astellas, Servier, Nohla; Consultant: AbbVie, Novartis, Agios, Incyte, Pfizer, Astellas, Jazz, BMS, Daiichi Sankyo, Inc, Servier, Celgene

Amir T. Fathi
Amir T. Fathi, MD
Director, Leukemia Program
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Grant/Research Support: Celgene, Agios, Takeda; Consultant: Celgene, Takeda, Agios, Jazz, Boston Biomedical, Astellas, Pfizer

Alexander Perl
Alexander Perl, MD
Associate Professor of Medicine
Division of Hematology/Oncology
Perelman School of Medicine
Leukemia Program
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA

Disclosures: Consultant: AbbVie, Actinium Pharmaceuticals, Agios, Arog, Astellas, Daiichi Sankyo, Inc, Jazz Pharmaceuticals, New Link Genetics, Novartis, Takeda

Keith Pratz
Keith Pratz, MD
Associate Professor of Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD

Disclosures: Grant/Research Support: AbbVie, Astellas, Agios, Millennium/Takeda; Consultant: AbbVie, Astellas, Boston Biomedical

Amer Zeidan
Amer Zeidan, MBBS, MHS
Assistant Professor of Medicine
Yale University School of Medicine
New Haven, CT

Disclosures: Grant/Research Support: Celgene, Takeda, Astellas, Acceleron, Incyte, Pfizer, Otsuka; Consultant: Agios, Celgene, Takeda, Astellas, Daiichi Sankyo, Inc, Acceleron, AbbVie, Incyte, Pfizer, Otsuka; Speakers Bureau: Takeda (expired)

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By